Please login to the form below

Not currently logged in
Email:
Password:

Meda appoints Maria Carell regional director for the US

She joins the Swedish speciality pharma company with management experience from Novartis, Actavis and Q-Med

Swedish speciality pharma company Meda has appointed Maria Carell to a senior management position at its US operations.

She has sat on the firm's board for almost a year and will now take up the role of regional director for the US as Meda waits for a decision from the Food and Drug Administration (FDA) on its rhinitis treatment Dymista.

The US regulator is due to decide in early May on Dymista (azelastine hydrochloride and fluticasone propionate), a nasal spray formulation for patients 12 years and older with seasonal allergic rhinitis.

"Maria Carell will be an important addition to the team that prepares the launch of Dymista in the US", said Anders Lönner, Meda's CEO.

She joins Meda with extensive experience in the health care sector, including management positions at Novartis, generics company Actavis and medical device firm Q-Med.

Following Carell's appointment to the US regional role she has declined re-election to Meda's board.

18th April 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
C+D

C+D has been informing, supporting and championing community pharmacy for more than 150 years. As an award-winning multi-media publisher we...

Latest intelligence

Leveraging HCP Transparency Insights to Drive Future Customer Investments
EFPIA’s disclosure requirements present an opportunity to assess strategy and effectiveness...
How did pharma use Twitter at #ASCO16?
Each year, ASCO’s Annual Meeting brings together 30,000 oncology professionals from around the world, here we explore the #ASCO16 hashtag and how pharma utilised the channel during this year's event....
WHITE PAPER: How to engage with HCPs more effectively
Shrinking budgets and limitations on the time HCPs can spend with sales reps is making traditional engagement methods more and more ineffective. So, in order to reach the unreachable, pharma...

Infographics